Figure 3 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma

Flow cytometry analysis of memory subsets of T cells in the different treatment groups of humanized HNSCC (YHIM-3003) and LUSC (YHIM-2010) PDX tumor of internally sacrificed mice (n = 5 in each treatment group). A, Heatmap of memory T cell subsets (central memory, effector memory, and effector T cells) and activation markers in the tumor samples of HNSCC PDX. B, Heatmap of memory T-cell subsets (central memory, effector memory, and effector T cells) and activation markers in the tumor samples of YHIM-2010. C, Factors that combination of amivantamab and pembrolizumab positively affected in each humanized PDX model and both models shared enhancement of CD8+ T central memory subset by combination therapy. D, Tumor reactive (CEA-stained) CD8 T cells in HNSCC PDX tumor were abundant in the combination treatment group and were significantly higher in proportion compared to the control group (8.28 ± 2.67 and 3.02 ± 0.75, respectively, P